“We found 3 well-documented cases of advanced cancers, confirmed by histopathologic review, where patients had unexpectedly long survival times after receiving high-dose intravenous vitamin C therapy. We examined clinical details of each case in accordance with National Cancer Institute (NCI) Best Case Series guidelines.
Tumour pathology was verified by pathologists at the NCI who were unaware of diagnosis or treatment. In light of recent clinical pharmacokinetic findings and in vitro evidence of anti-tumour mechanisms, these case reports indicate that the role of high-dose intravenous vitamin C therapy in cancer treatment should be reassessed.” [Emphasis added.] Yet S 510 and S 3767, “food safety” bills in the US and C-36, a “product safety” bill in Canada, would remove access to this treatment and to all supplements in adequate enough doses to treat disease.'
Read more...
Related Post:
Widget by [ Iptek-4u ]
